LRRC32 and cancer: The inhibition of human Treg cell immunosuppressive activity by monoclonal antibodies against GARP/TGFβ complexes54 implicates these antibodies may serve as therapeutic tools to boost immune responses to cancer via a mechanism of action distinct from the currently available immunotherapies.